Hikma Pharmaceuticals (LON:HIK) Stock Price Passes Above 200-Day Moving Average – Time to Sell?

Hikma Pharmaceuticals PLC (LON:HIK) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 2,016.45 ($26.11) and traded as high as GBX 2,034 ($26.33). Hikma Pharmaceuticals shares last traded at GBX 2,010 ($26.02), with a volume of 35,338,895 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Berenberg Bank reiterated a “buy” rating and issued a GBX 2,560 ($33.14) price target on shares of Hikma Pharmaceuticals in a research report on Monday, March 10th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a research note on Friday, March 7th.

Hikma Pharmaceuticals Trading Up 1.2 %

The company’s 50 day moving average price is GBX 2,178.16 and its two-hundred day moving average price is GBX 2,016.45. The firm has a market cap of £5.57 billion, a PE ratio of 19.72, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82.

Hikma Pharmaceuticals Increases Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, May 1st. Investors of record on Thursday, March 20th will be given a $0.48 dividend. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.32. This represents a yield of 1.8%. The ex-dividend date of this dividend is Thursday, March 20th. Hikma Pharmaceuticals’s dividend payout ratio is 60.84%.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.